VI-60

• Description :

  VI-60 is a dual, orally active inhibitor of cPLA2 and COX-2, which reveals an anti-inflammtory efficacy through the inhibition of p38 MAPK/cPLA2/COX-2/PGE2 pathway[1].

• UNSPSC :

  12352005

• Target :

  COX; Phospholipase

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation; Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/vi-60.html

• Solubility :

  10 mM in DMSO

• Smiles :

  CCCCC/C=C\C/C=C\C/C=C\C/C=C\CC/C=C(C(F)(F)F)/OC(C(C)C1=CC=C(C(C2=CC=CC=C2)=O)C=C1)=O

• Molecular Formula :

  C37H43F3O3

• Molecular Weight :

  592.73

• References & Citations :

  [1]Cai N, et al., Discovery of novel NSAID hybrids as cPLA2/COX-2 dual inhibitors alleviating rheumatoid arthritis via inhibiting p38 MAPK pathway. Eur J Med Chem. 2024 Jan 24;267:116176.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  COX-2; Phospholipase A